Real-World Outcomes of Oral Azacitidine Maintenance in AML Presented at ASH 2024

In an interview with Targeted Oncology^TM, Fatima Tuz Zahra, MD, hematology/oncology fellow at Moffitt Cancer Center, University of South Florida, Tampa, discusses the methods and design of a retrospective analysis of 65 patients with acute myeloid leukemia (AML) treated with oral azacitidine maintenance after achieving complete remission, which is being presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition.

The study was conducted between September 2020 and June 2024 at Moffitt Cancer Center and its findings align with those seen in the QUAZAR AML-001 trial (NCT01757535), which previously demonstrated significant benefits in overall survival and relapse-free survival.

Results from the study ultimately revealed good outcomes for younger patients with AML in their 50s. Further, while the QUAZAR AML trial primarily included older patients with AML, this study suggests that younger patients can also benefit from oral azacitidine maintenance.

Transcription:

0:10 The therapy with oral azacitidine for maintenance was approved following the phase 3 QUAZAR AML study [NCT01757535], which demonstrated definitive benefits in overall survival and relapse-free survival. For our study, we looked at patients treated between September 2020 and June 2024. Some patients had started therapy recently, so that was the timeline we defined. Retrospectively, we reviewed our pharmacy records to identify patients prescribed oral azacitidine. We included only those who completed at least 1 cycle of therapy, excluding those who used it briefly to provide a clearer insight into treatment outcomes.

1:01 | We included adults 18 years or older and excluded patients who had undergone allotransplant to avoid confounding their survival outcomes. After identifying our cohort, we conducted descriptive statistics and performed survival analysis using Kaplan-Meier methods.

REFERENCE:

1. Zahra FT, Ong F, Walgenbach D, et al. Real world outcomes of oral azacitidine maintenance therapy for acute myeloid leukemia: A single center experience. Presented at: ASH Annual Meeting. December 7-10, 2023. Abstract: 2415.